Evaluation of the economic and social burden of chronic obstructive pulmonary disease (COPD)

Tachkov, Konstantin; Kamusheva, Maria; Pencheva, Ventsislava; Mitov, Konstantin

doi:10.1080/13102818.2017.1335616

Cited by 14 publications

(14 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study estimated the total cost of traumatic brain injury in the Netherlands at USD $433.8 million per year (Scholten, Haagsma, Panneman, van Beeck & Polinder, 2014). A study in Bulgaria calculated monetary value of DALYs lost from mild, moderate and severe chronic obstructive pulmonary disease (COPD) to be Euro 3596.52, Euro 34204.01 and Euro 51,332.20 per patient, respectively (Tachkov, Kamusheva, Pencheva & Mitov, 2017). (Kirigia, Mburugu & Huka, 2017).…”

Section: "[Insert Figure 1]"mentioning

confidence: 99%

The monetary value of disability-adjusted-life-years lost in Kenya in 2017.pdf

Kirigia¹,

Muthuri²

2019

Preprint

View full text Add to dashboard Cite

Diseases and injuries exert a heavy health and economic burden on Kenya. The specific objectives of this study were: (a) to estimate the monetary value of disability-adjusted-life-years (DALYs) lost from all causes in 2017 with ongoing implementation of United Nations Sustainable Development Goal SDG 3;and (b) to estimate the reductions in monetary value of DALY losses in Kenya assuming diseases and injuries related to SDG3 targets are achieved by 2030. A variant of human capital (or net output) analytical framework was applied to monetarily value DALYs lost from 166 diseases and injuries. The 17.9 million DALYs lost in Kenya in 2017 had a total monetary value of Int$ 67,012,790,388. Approximately, 56.64% of the monetary value of DALYs lost emanated from communicable, maternal, neonatal, and nutritional diseases; 35.94% from non-communicable diseases; and 7.42% from injuries. We estimate that full attainment of the five SDG 3 targets would lead to a Int$ 21.52 billion (45.42%) decrease in the SDG3-related monetary value of DALYs lost by 2030. There is urgent need for health policy-makers to use this kind of evidence when advocating among public and private sectors for increased spending on health development. Word Count: 6,753 ORCID iDJoses Muthuri Kirigia -https://orcid.org/

show abstract

Section: "[Insert Figure 1]"mentioning

confidence: 99%

The monetary value of disability-adjusted-life-years lost in Kenya in 2017.pdf

Kirigia¹,

Muthuri²

2019

Preprint

View full text Add to dashboard Cite

show abstract

“…An ambispective observational study of real-life therapy on a representative cohort of 426 patients with COPD was performed to investigate their exacerbation and hospitalization in relation to the prescribed pharmacotherapy. The detailed methodology of the study was explained elsewhere, but in general, the representative cohort from 17 country sites was selected and observed by pulmonologists for current and past COPD therapy in 2014-2015, with a lot of information of patients' characteristics regarding severity of disease, exposure to risk, smoking habits, hospitalizations, exacerbations and cost variables [11,23].…”

Section: Micro Analysismentioning

confidence: 99%

Micro and macro analysis on the burden of COPD hospitalizations on the Bulgarian healthcare system

Tachkov

Dimitrova

Mitov

et al. 2019

Biotechnology & Biotechnological Equipment

Self Cite

View full text Add to dashboard Cite

The aim of this study was to investigate the economic burden of Chronic Obstructive Pulmonary Disease (COPD)-related hospitalizations on a macro and micro level. Macro analysis was performed on the rate of DDD utilisation of COPD medicines, time of their inclusion in the reimbursement lists and the number of hospitalizations. On a micro level, a study of 426 patients with COPD was conducted to investigate the exacerbation and hospitalization rate relative to pharmacotherapy. A regression model, descriptive analysis, and Kruskal-Wallis non-parametric analysis were conducted. New drugs enter the market relatively quickly but are slow to be introduced into prescribing practices. The medicines' utilization in Bulgaria has increased from 20 to 21 million DDD for all therapeutic groups, especially for long-acting beta-agonists/ long-acting muscarinic antagonists (LABA/LAMA) fixed-dose combinations. A marked increase in hospitalization rates was observed despite lower numbers of registered and monitored COPD patients nationally. However, the hospitalization rates due to exacerbations remained around 18-19%. Variation was observed in the number of hospitalizations for the studied period: increasing during the period 2013-2014 and decreasing over the following two years. This trend was also observed for the number of health insured COPD patients. The hospitalization costs increased from 5.2 to 5.7 million BGN. A statistically significant decrease in the number of hospitalizations for LAMA/LABA patients vs. LABA/inhaled corticosteroids (ICS) patients was observed. Overall, frequent hospitalizations increased the total cost of COPD therapy. Patients on new medicines with improved inhaler devices seem to suffer fewer hospitalizations.

show abstract

“…Since publishing the global burden of disease methodology and creating the Disability Adjusted Life Years (DALY) many studies used this as measure for the evaluation of the burden of diseases on the society [8,9]. There is no information about the burden of glaucoma on the Bulgarian society that provokes our study.…”

Section: Biomedical Research 2018; 29 (12): 2578-2581mentioning

confidence: 99%

Assessment of the social and economic burden of glaucoma in Bulgaria

Grekova¹,

Andreevska²,

Petrova³

et al. 2018

biomedicalresearch

View full text Add to dashboard Cite

Introduction: Glaucoma commonly refers not to a single disease, but to a group of disorders that have certain common features, in particular cupping and atrophy of the optic nerve head; characteristic visual field loss. Quality of life in glaucoma is affected earlier than previously thought. Aim of this study is to assess the social and economic burdens of glaucoma in Bulgaria. Materials and methods: The study is a macro observational study of the number of registered and treated patients with glaucoma in Bulgaria, their cost and resulting Disability adjusted life years due to glaucoma. Results: In 2016 the number of women with glaucoma is 51,321 and the number of male is 27,166. Almost twice as large is the percentage of female suffering from glaucoma-65%, compared to the percentage of male-35%. Incidence grows exponentially and in 2014 newly diagnosed were 7975 glaucoma patients, in 2015-7492 patients, and in 2016-7407 patients. Proportion of newly diagnosed is between 0.08% and 3.27% and depends on the age group. Disability adjusted life years for all registered glaucoma patients account for 674,422 and every patient lives on average 10 y in full disability due to visual loss that generates economic losses of $79000 per person for life time period. Conclusions: Glaucoma is a disease that generates economic and social loses to the society and the patients. Bulgarian glaucoma patient's pays half of their pharmacotherapy and bear 10 Disability adjusted life years during their entire life.

show abstract

Evaluation of the economic and social burden of chronic obstructive pulmonary disease (COPD)

Cited by 14 publications

References 24 publications

The monetary value of disability-adjusted-life-years lost in Kenya in 2017.pdf

The monetary value of disability-adjusted-life-years lost in Kenya in 2017.pdf

Micro and macro analysis on the burden of COPD hospitalizations on the Bulgarian healthcare system

Assessment of the social and economic burden of glaucoma in Bulgaria

Contact Info

Product

Resources

About